MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Income Overview

Net Income
-$35,059,852
EPS
-$2.26
Unit: Dollar

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Research and development expenses
901,144 -274,634.5* 619,693 651,784
General and administrative expenses
11,284,550 5,424,982* 1,224,546 2,012,120
Total operating expenses
12,185,694 5,150,347.5 1,844,239 2,663,904
Loss from operations
-12,185,694 -5,150,347.5* -1,844,239 -2,663,904
Unrealized gain (loss)from changes in fair value of digital assets
-22,078,601 453,087* NaN NaN
Realized gain on sale of digital assets
15,100 5,597,696.5* NaN NaN
Trading gains, net
2,029 24.25* NaN NaN
Foreign currency gains/(losses), net
-1,567 -130.25* NaN NaN
Change in fv of warrant liability
NaN 11,188.5* -12,859 -9,518
Change in fv of derivative
-48,279 -13,786.5* NaN NaN
Interest income
7 85.5* 56,426 15,247
Interest expense
859,405 238,978.5* 6,301 23,054
Total other income (expense)
-22,874,158 5,814,382.5* 62,984 1,711
Net gain
-35,059,852 664,035 -1,781,255 -2,662,193
Basic EPS
-2.26 0.068 -0.14 -0.26
Diluted EPS
-2.26 0.068 -0.14 -0.26
Basic Average Shares
15,513,389 9,700,611 12,575,983 10,369,127
Diluted Average Shares
15,513,389 9,700,611 12,575,983 10,369,127
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

Net gain-$35,059,852 Total other income(expense)-$22,874,158 Loss from operations-$12,185,694 Change in fv ofderivative-$48,279 Realized gain on sale ofdigital assets$15,100 Trading gains, net$2,029 Interest income$7 Unrealized gain (loss)fromchanges in fair value of...-$22,078,601 Interest expense$859,405 Total operatingexpenses$12,185,694 Foreign currencygains/(losses), net-$1,567 General andadministrative expenses$11,284,550 Research and developmentexpenses$901,144

Apimeds Pharmaceuticals US, Inc. (APUS)

Apimeds Pharmaceuticals US, Inc. (APUS)